ABP 206
Sponsors
Amgen Inc., Amgen
Conditions
MelanomaUnresectable or Metastatic Melanoma
Phase 3
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
CompletedNCT05907122
Start: 2023-07-26End: 2025-10-31Updated: 2026-03-27
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma
Active, not recruitingCTIS2023-503288-40-00
Start: 2024-01-26Target: 396Updated: 2025-11-18
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Active, not recruitingNCT06054555
Start: 2023-11-02End: 2028-01-25Updated: 2026-01-12